

1 **Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals**

2
3 Naoyuki Taira¹, Sakura Toguchi¹, Mio Miyagi¹, Tomoari Mori², Hiroaki Tomori³, Koichi
4 Oshiro⁴, Osamu Tamai⁵, Mitsuo Kina⁶, Masatake Miyagi⁷, Kentaro Tamaki⁸, Mary K
5 Collins⁹, and Hiroki Ishikawa¹

6
7
8 ¹ *Immune Signal Unit, Okinawa Institute of Science and Technology, Graduate University*
9 *(OIST), Onna-son, Okinawa, Japan.*

10 ² *Research Support Division, Occupational Health and Safety, OIST, Onna-son, Okinawa,*
11 *Japan*

12 ³ *Yaesu Clinic, Naha-city, Okinawa, Japan*

13 ⁴ *Ohama Daiichi Hospital, Naha-city, Okinawa, Japan*

14 ⁵ *Akebono Clinic, Naha-city, Okinawa, Japan*

15 ⁶ *Kina Clinic, Naha-city, Okinawa, Japan*

16 ⁷ *Arakawa Clinic, Naha-city, Okinawa, Japan*

17 ⁸ *Naha-Nishi Clinic, Department of Breast Surgery, Naha-city, Okinawa, Japan*

18 ⁹ *Research Support Division, Office of the Provost, OIST, Onna-son, Okinawa, Japan.*

19
20
21 Corresponding author

22 Hiroki Ishikawa PhD

23 hiroki.ishikawa@oist.jp

24 Tel: 81-098-966-1601

37 **Abstract**

38 Pre-existing SARS-CoV-2-specific T cells, but not antibodies, have been detected in some
39 unexposed individuals. This may account for some of the diversity in clinical outcomes
40 ranging from asymptomatic infection to severe COVID-19. Although age is a risk factor
41 for COVID-19, how age affects SARS-CoV-2-specific T cell responses remains unknown.
42 We found that some pre-existing T cell responses to specific SARS-CoV-2 proteins, Spike
43 (S) and Nucleoprotein (N), were significantly lower in elderly donors (>70 years old) who
44 were seronegative for S than in young donors. However, substantial pre-existing T cell
45 responses to the viral membrane (M) protein were detected in some elderly donors. These
46 responses likely compensate for loss of T cell responses specific to S and N. In contrast,
47 young and elderly donors exhibited comparable T cell responses to S, N, and M proteins
48 after infection with SARS-CoV-2. M-specific responses were mediated by CD4 T cells
49 producing interferon- γ in both seronegative and seropositive individuals. T cells in
50 seronegative elderly donors responded to various M-derived peptides, while the response
51 after SARS-CoV-2 infection was apparently focused on a single peptide. These data
52 suggest that diversity of target antigen repertoire for pre-existing SARS-CoV-2-specific
53 T cells declines with age, but the magnitude of pre-existing T cell responses is maintained
54 by T cells reactive to specific viral proteins such as M. A better understanding of the role
55 of pre-existing SARS-CoV-2-specific T cells that are less susceptible to age-related loss

56 may contribute to development of more effective vaccines for elderly people.

57

58 **Introduction**

59 There is extensive individual variation in severity of coronavirus disease 2019 (COVID-
60 19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging
61 from asymptomatic infection to fatal pneumonia (1). Various factors, including age, sex,
62 and comorbidities such as obesity and diabetes, influence the risk of severe COVID-19
63 (2-4). For example, morbidity and mortality among the elderly are significantly higher
64 than among the young (2). Consideration of protective measures for individuals
65 vulnerable to COVID-19 should be particularly important to control the pandemic (5).
66 However, the cellular and molecular bases of the variable risk of COVID-19 remain
67 poorly understood.

68 T cells are assumed to mediate both protective and pathogenic immune responses
69 to SARS-CoV-2 infection (6, 7). The magnitude and quality of T cell responses induced
70 by SARS-CoV-2 infection are highly heterogeneous and are likely associated with
71 COVID-19 clinical outcomes. For example, SARS-CoV-2-specific T cell numbers and
72 their interferon- γ (IFN- γ) expression in severe COVID-19 patients are lower than in mild
73 COVID-19 patients (8-10). Furthermore, asymptomatic COVID-19 patients tend to have

74 increased SARS-CoV-2-specific T cells expressing higher levels of IFN- γ compared to
75 symptomatic patients (11). This individual variation in T cell responses may be partly
76 explained by heterogeneity in levels of pre-existing SARS-CoV-2-reactive T cells.

77 Some individuals who have not been exposed to SARS-CoV-2 have nonetheless
78 acquired SARS-CoV-2-reactive T cells, probably through exposure to other common cold
79 coronaviruses (12-14). Pre-existing CD4 and CD8 memory T cells, specific to various
80 SARS-CoV-2 proteins, including the structural proteins, Spike (S), Membrane (M), and
81 Nucleoprotein (N), have been detected with significant individual variation (D. Wyllie et
82 al., manuscript posted on medRxiv DOI: 10.1101/2020.11.02.20222778). These pre-
83 existing SARS-CoV-2-reactive T cells are associated with immune protection against
84 COVID-19; however, in other cases, they may exacerbate COVID-19 severity (15, 16).
85 As many of the current vaccines express the SARS-CoV-2 S protein, only pre-existing S-
86 reactive T cells are activated by these vaccines (Refs. 17 and L. Loyal et al., manuscript
87 posted on medRxiv DOI: 10.1101/2021.04.01.21252379). Several studies have reported
88 age-related differences in SARS-CoV-2-specific T cell responses in COVID-19 patients
89 (Refs. 9 and C. A. Cohen et al., manuscript posted on medRxiv DOI:
90 10.1101/2021.02.02.21250988); however, the effect of age on pre-existing SARS-CoV-
91 2-reactive T cells remains unknown.

92 In this study, we compared frequencies of T cells reactive to SARS-CoV-2 S, N,
93 and M antigens between young and elderly donors. The relatively elderly Okinawan
94 population, and the moderate rate of SARS-CoV-2 infection in Okinawa, allowed us to
95 examine pre-existing SARS-CoV-2-specific T cells in a cohort of elderly (>70 years old)
96 individuals. We found that pre-existing T cell responses to S and N antigens are
97 significantly impaired in elderly donors compared to young donors, but a proportion of
98 elderly donors exhibit significant, high levels of M-reactive T cell responses. These data
99 provide new insights into age-related alteration of pre-existing SARS-CoV-2-specific T
100 cells.

101

102

103

104

105

106

107

108

109

110 **Methods**

111 **Subjects**

112 The study design was approved by the Okinawa Institute of Science and Technology,
113 Graduate University (OIST) human subjects ethics committee (applications HSR-2020-
114 024, HSR-2020-028). All donors provided informed written consent. Young (20 to 50
115 years of age, n=66) and elderly volunteers (over 70 years of age, n=52) were recruited in
116 Okinawa, Japan, between October, 2020 and April, 2021. 90 donors (48 young and 42
117 elderly) had no history of COVID-19, while 28 donors (18 young and 10 elderly) who
118 recovered from COVID-19 had positive COVID-19 PCR test results 1-3 months before
119 blood collection. Plasma from each donor was tested for SARS-CoV-2-specific antibodies
120 using SARS-Cov-2 Antibody Detection Kits (KURABO RF-NC001, RF-NC002) or
121 Cellex qSARS-Cov-2 IgG/IgM Cassette Rapid Tests (Cellex 5513C). Four (3 young and
122 1 elderly) of 90 donors who had no history of COVID-19 and 26 (16 young and 10
123 elderly) of 28 donors who had recovered from COVID-19 were seropositive for SARS-
124 CoV-2 S antigen. Based on antibody test results, donors were grouped into seronegative
125 young (n=45, 40 % male, 60% female; mean age 38 years, age range 23-49 years),
126 seronegative elderly (n=41, 17 % male, 83% female; mean age 81 years, age range 70-93
127 years), seropositive young (n=19, 63 % male, 37% female; mean age 41 years, age range

128 20-50 years), and seropositive elderly (n=11, 45 % male, 55% female; mean age 78 years,
129 age range 70-91 years).

130

131 **Peripheral blood mononuclear cells (PBMCs) and plasma isolation.**

132 Blood samples were collected in heparin-coated tubes (TERUMO;
133 VP-H100K). PBMCs and plasma were separated using Leucosep tubes pre-filled with
134 Ficoll-Paque Plus (Greiner; 163288). After adding 5 mL of blood and 3 mL of AIM-V
135 medium (Thermo; 12055091), Leucosep tubes were centrifuged at 1,000 g at room
136 temperature for 10 min. The white layer containing PBMCs was collected, washed with
137 10 mL AIM-V medium and centrifuged for 7 min at 600 g, followed by a second washing
138 with centrifugation for 7 min at 400 g. PBMC pellets were resuspended in 500 μ L CTL
139 test medium (Cellular Technology Limited (CTL); CTLT-010). Fresh PBMCs were used
140 for IFN- γ ELISpot assays. PBMCs used for flow cytometry analysis and epitope mapping
141 analysis were stored with CTL-cryo ABC media (CTL; CTLC-ABC) in liquid nitrogen.

142

143 **IFN- γ ELISpot assay**

144 Peptide pools for SARS-CoV-2 S (JPT; PM-WCPV-S-1), N (Miltenyi;130-126-698), and
145 M (Miltenyi;130-126-702) proteins dissolved in DMSO (500 μ g/mL for S) or water (50

146 $\mu\text{g}/\text{mL}$ for N and M) were used for cell stimulation. IFN- γ ELISpot assays were performed
147 using Human IFN- γ Single-Color Enzymatic ELISpot kits (CTL; hIFN γ -2M), according
148 to the manufacturer's instructions. Briefly, freshly isolated PBMCs ($1-4 \times 10^5$ cells per
149 well) were stimulated with $1\mu\text{g}/\text{mL}$ peptide solutions for each SARS-CoV-2 protein for
150 18-20 h. For each sample analysis, negative controls (cells treated with equimolar
151 amounts of DMSO) and positive controls (cells treated with 50 ng/mL phorbol 12-
152 myristate 13-acetate (PMA) and $1\mu\text{g}/\text{mL}$ ionomycin) were included. After incubation,
153 plates were washed and developed with detection reagents included in the kits. Spots were
154 counted using a CTL ImmunoSpot S6 Analyzer. Antigen-specific spot counts were
155 determined by subtracting background spot counts in a negative control well from the
156 wells treated with peptide pools. If >30 spots/ 10^6 PBMCs in the negative control well or
157 <30 spots/ 10^6 PBMCs in the positive control well were detected, sample data were
158 excluded from analysis.

159

160 **Flow cytometry**

161 Frozen PBMCs were thawed, washed with CTL wash supplement (CTL; CTL-W-010),
162 and rested in CTL test medium overnight. Then, cells were resuspended in RPMI1640
163 (Gibco) medium supplemented with 5% (v/v) human AB-serum (PAN-Biotech; P30-

164 2901), seeded into 96-well, U-bottom culture plates (10^6 cells per well), and either left
165 unstimulated (cells treated with equimolar amounts of DMSO) or stimulated with $1\mu\text{g}/\text{mL}$
166 SARS-CoV-2 M peptide pool for 7 h in the presence of $1\mu\text{g}/\text{mL}$ anti-CD40 (5C3;
167 Biolegend; 334302) and $1\mu\text{g}/\text{mL}$ anti-CD28 antibodies (CD28.2; Biolegend; 302934).
168 Brefeldin A ($1\mu\text{g}/\text{mL}$) (Biolegend; 420601) was added for the last 2 h. After stimulation,
169 cells were incubated with anti-Fc receptor-blocking antibody (Biolegend; 422301) and
170 NIR-Zombie (Biolegend; 423106) and stained with anti-CD3 (OKT3; Biolegend; 1:200),
171 anti-CD4 (clone PPA-T4; Biolegend; 1:200), anti-CD8 (SK1; Biolegend; 1:200), anti-
172 CD45RA (HI100; Biolegend; 1:100), and anti-CCR7 (G043H7; Biolegend; 1:100)
173 antibodies. For intracellular cytokine analysis, cells were subsequently fixed and
174 permeabilized using Foxp3 Staining Buffer Sets (eBioscience; 00-5253-00) and stained
175 with anti-IFN- γ (B27; BD; 1:100), anti-TNF- α (MAb11; Biolegend; 1:20) and anti-IL-2
176 (MQ1-17H12; Biolegend; 1:20) antibodies. Samples were analyzed on a Fortessa X-20
177 (BD), and data were analyzed with FlowJo software version 10.7.1 (FlowJo LLC).

178

179 **Matrix peptide pools of SARS-CoV-2 M**

180 Matrix peptide pools included in Epitope Mapping Peptide Set SARS-CoV-2 (VME1)
181 (JPT EMPS-WCPV-VME-1) were used to analyze M epitopes recognized by T cells.

182 PBMCs ($0.5-1.5 \times 10^5$) were stimulated with 1 $\mu\text{g}/\text{mL}$ of each M matrix peptide pool (15
183 pools of 6-8 peptides) for 18 h and subjected to IFN- γ ELISpot assays.

184

185 **Statistical analysis**

186 Unpaired t tests or Mann-Whitney U tests were performed using GraphPad Prism 9.1.0
187 software. Statistical details are provided in figure legends.

188

189

190

191

192

193

194

195

196

197

198

199

200

201 **Results**

202 **Age-related differences in SARS-CoV-2-specific T cell responses**

203 To assess whether there are age-related differences in SARS-CoV-2-specific T cell
204 responses, we collected peripheral blood from young (20 to 50 years of age) and elderly
205 (>70 years of age) donors in Okinawa between October 2020 and April 2021. These
206 included 18 young and 10 elderly donors who had recovered from mild COVID-19 1-3
207 months prior to blood collection. Antibody tests using freshly purified sera showed that
208 93% of donors with previously diagnosed COVID-19 and 4% of those without, were
209 seropositive for SARS-CoV-2 Spike (S). Then we divided donors into 4 groups: young
210 seronegative (n=45), elderly seronegative (n=41), young seropositive (n=19), and elderly
211 seropositive (n=11).

212 To compare SARS-CoV-2-specific T cell responses between age groups we
213 performed Interferon- γ (IFN- γ) ELISpot assays using freshly purified peripheral blood
214 mononuclear cells (PBMCs) stimulated with each of 4 peptide pools covering the major
215 viral structural proteins [N-terminal S (S1), C-terminal S (S2), Membrane (M), or
216 Nucleoprotein (N)]. First, we analyzed the sum of spots formed by IFN- γ -expressing cells
217 reactive to S1, S2, N, or M antigens (hereafter referred to as spots of SNM-reactive T

218 cells), indicating the magnitude of SARS-CoV-2-specific T cell responses in each donor.
219 Almost all seropositive donors exhibited strong T cell responses to SARS-CoV-2 antigens
220 regardless of age; the frequency of SNM-reactive spots was >40 per 10⁶ PBMCs in 92%
221 of seropositive donors. The frequency of SNM-reactive T cells in seronegative donors
222 was more variable than in seropositive donors, but a substantial proportion of
223 seronegative donors exhibit T cell responses comparable to those of seropositive donors
224 (53% of young donors and 42% of elderly donors had >40 spots per 10⁶ PBMCs). In both
225 seronegative and seropositive populations, there were no significant differences in the
226 frequency of SNM-reactive T cells between young (seronegative; median:53, IQR:21-96,
227 seropositive; median:312, IQR:75-1509) and elderly (seronegative; median:32, IQR:7-
228 331, seropositive; median:778, IQR:351-2392) (Fig. 1A, 1B).

229 Next, we compared frequencies of T cells reactive to individual viral antigens
230 between young and elderly donors. Among seronegative donors, the frequencies of S-2-
231 and N-reactive T cells were significantly lower in elderly than in young persons (Fig. 1B).
232 However, there were no significant differences in the frequencies of S-1- and M-reactive
233 T cells between seronegative young and elderly donors (Fig. 1B). Consistent with
234 previous reports (12), T cell responses to S-2 were higher than S-1 in the seronegative
235 population (Fig. 1B). Frequencies of T cells specific to S1, S2, N, and M were comparable

236 between seropositive young and elderly donors (Fig. 1B).

237 We also analyzed intraindividual immunodominance of each SARS-CoV-2
238 antigen in donors who had >40 spots per 10⁶ PBMCs. Remarkably, M-specific responses
239 were dominant in 6/23 young and 12/14 elderly seronegative donors (Fig. 2A). In contrast,
240 T cell responses specific to S-1 and S-2 were more prominent than M in seropositive
241 donors (Fig. 2B). Taken together, these data suggest that although SARS-CoV-2 infection
242 can induce comparable T cell responses to various viral antigens in young and elderly
243 individuals, pre-existing memory T responses specific to SARS-CoV-2 S and N antigens
244 decrease in elderly people, while M-specific T cell responses are maintained.

245

246 **Phenotypes of M-reactive T cells**

247 Given that a proportion of seronegative donors exhibited M-specific responses
248 comparable to those of seropositive donors, we compared phenotypes of M-reactive T
249 cells by flow cytometry analysis. We analyzed 5 seronegative (1 young and 4 elderly) and
250 5 seropositive (2 young and 3 elderly) donors who had high responses to the M peptide
251 pool (M responders). We stimulated PBMCs with the M peptide pool and stained cells
252 with anti-CD4 or anti-CD8 antibodies, followed by intracellular cytokine staining with
253 anti-IFN- γ antibody. Upon stimulation with the M peptide pool, CD4 T cells but not CD8

254 T cells significantly increased expression of IFN- γ in both seronegative and seropositive
255 M responders and at comparable levels (Fig. 3A, 3B).

256 We next analyzed CD45RA and CCR7 expression to determine proportions of
257 naïve and memory cells among M-reactive CD4 T cells. Although there was significant
258 variation between individuals in proportions of M-reactive CD4 T cells exhibiting naïve
259 (CD45RA⁻ CCR7⁺), effector memory (CD45RA⁺ CCR7⁻), and central memory
260 (CD45RA⁺ CCR7⁺) phenotypes, all M responders had M-reactive memory T cells (Fig.
261 3C). There was no obvious difference in the proportion of naïve, effector memory, and
262 central memory CD4 T cells between seronegative and seropositive M responders (Fig.
263 3C).

264 We also analyzed frequencies of cells expressing IL-2 and TNF- α among M-
265 reactive CD4 T cells. Although several donors showed increased IL-2 and TNF- α
266 expression upon stimulation with M in both seronegative and seropositive M responders,
267 in seropositive donors, only IL-2 reached statistical significance (Fig. 3D). Seronegative
268 and seropositive M-responders showed no detectable difference in IL-2 and TNF- α
269 expression in T cells stimulated with M (Fig. 3D). Expression of TNF- α and IL-2 in IFN-
270 γ -expressing CD4 T cells was comparable between seronegative and seropositive M
271 responders (Fig. 3E). These data indicate that M-reactive T cell responses are mediated

272 by CD4 T cells expressing IFN- γ in both seronegative and seropositive M responders,
273 suggesting that pre-existing M-reactive T cells and SARS-CoV-2-induced memory M-
274 specific T cells might serve similar functions in SARS-CoV-2 infection.

275

276 **Epitopes of SARS-CoV-2 M protein**

277 To compare epitopes recognized by M-reactive T cells of seronegative and
278 seropositive donors, we stimulated PBMCs isolated from M responders with SARS-
279 CoV-2 M matrix pools (15 pools of 6-8 peptides) where each of 56 M-derived peptides
280 (15-mers) is allocated to 2 different pools. In seropositive M responders, stimulation
281 with pools 5 and 13 induced high levels of IFN- γ responses (Fig. 4A). These matrix
282 pools shared a single peptide, M₁₄₅₋₁₆₀, suggesting that the M₁₄₅₋₁₆₀, which was
283 previously identified as an immunodominant viral epitope in COVID-19 convalescent
284 patents (18), is the epitope recognized by T cells of seropositive M responders. In
285 contrast, in seronegative M responders, stimulation of PBMCs with many M matrix
286 pools induced comparable IFN- γ responses (Fig. 4B), suggesting that various M
287 epitopes are recognized by pre-existing T cells.

288

289

290

291 **Discussion**

292 Our data indicate that a fraction of elderly donors possess significantly high
293 levels of pre-existing SARS-CoV-2 M-specific T cell responses, though the frequency of
294 pre-existing SARS-CoV-2 S- and N-specific T cells in this population is lower. Other
295 recent studies have also reported an age-related decline of S-specific pre-existing T cells
296 (Refs. 19 and L. Loyal et al., manuscript posted on medRxiv DOI:
297 10.1101/2021.04.01.21252379). These data suggest that pre-existing T cells specific to
298 SARS-CoV-2 are heterogeneously affected by age in a target antigen-dependent manner.
299 There was no obvious difference in the sum of IFN- γ -expressing cells specific to S, N,
300 and M antigens, suggesting that abundant M-specific T cells can compensate for the loss
301 of S- and N-specific T cells, at least in the magnitude of T cell-mediated IFN- γ production,
302 in elderly individuals. Taken together, these data suggest that the diversity of target
303 antigen repertoire for pre-existing T cells may decline with age, but the magnitude of pre-
304 existing T cell responses can be maintained with T cells specific to certain viral proteins
305 such as M.

306 As the frequency of pre-existing T cells specific to viral structural proteins S, N,
307 and M is associated with protection from SARS-CoV-2 infection (D. Wyllie et al.,

308 manuscript posted on medRxiv DOI: 10.1101/2020.11.02.20222778) , focused M
309 responses might be particularly important for protection of elderly individuals who have
310 lower responses to S and N. Flow cytometry analyses revealed that CD4 T cells mainly
311 mediate M-specific T cell responses, and their naïve/memory phenotypes and their
312 capacity to produce IFN- γ , IL-2, and TNF- α cytokines were comparable between
313 seronegative and seropositive groups. The phenotypic similarity suggests that pre-
314 existing M-reactive T cells may serve similar functions to SARS-CoV-2-induced M-
315 specific memory T cells. We speculate that pre-existing M-specific CD4 T cells play a
316 protective role in SARS-CoV-2 infection by promoting cellular immunity through IFN- γ
317 production and humoral immunity by providing T cell help to S- and N-specific B cells
318 via linked recognition.

319 However, we cannot exclude the possibility that pre-existing M-specific T cells
320 are harmful for some elderly individuals. Several studies suggest that pre-existing SARS-
321 CoV-2-specific T cells are detrimental in COVID-19 (8). In particular, the frequency of
322 M-specific T cells in COVID-19 patients is thought to be a risk factor, as it is correlated
323 with age and severity of disease (8), although how pre-existing M-specific T cells affect
324 magnitude, kinetics and functions of M-specific T cell responses in COVID-19 patients
325 remains unclear. Thus, both protective and pathogenic functions of pre-existing M-

326 specific T cells can be speculated. A longitudinal comparison of susceptibility and
327 symptom severity of COVID-19 between individuals with and without high pre-existing
328 M-specific T cell responses might provide insights into this issue.

329 Despite defects in pre-existing T cell responses to S and N, most elderly donors
330 who recovered from mild COVID-19 had abundant T cells specific to S and N antigens
331 at levels comparable to those of young donors, suggesting that elderly individuals can
332 induce T cell responses against S and N antigens upon SARS-CoV-2 infection. However,
333 our analysis is limited to only a few patients who had recovered from mild COVID-19.
334 Therefore, the relationship between age-related alteration of pre-existing T cells and T
335 cell responses during infection in patients with diverse clinical outcomes of COVID-19
336 should be investigated in a larger, statistically valid test population.

337 Whether diverse SARS-CoV-2-induced T cell clones can mediate long-lasting
338 memory responses should be addressed in future studies. It has recently been shown that
339 SARS-CoV-2-induced memory T cells persist at least 6 months after infection (20).
340 Interestingly, SARS-CoV-1 infection induces long-lasting (>11 years) CD8 memory T
341 cells specific to M₁₄₁₋₁₅₅ peptide (21). Our data show that the overlapping peptide (M₁₄₅₋
342 ₁₆₀) is immunodominant in SARS-CoV-2 infection, which is consistent with a recent study
343 showing CD4 T cell responses to the M₁₄₅₋₁₆₀ peptide in convalescent COVID-19 patients

344 (18). The amino acid sequence of M₁₄₅₋₁₆₀ peptide from SARS-CoV-2 shows high
345 homology with SARS-CoV-1 and other coronaviruses (SARS-CoV-1: 81.3%, NL63:
346 33.0% , OC43: 47.0%, 229E: 22.7%, HKU1: 47.0%). This short M peptide is likely a
347 potent inducer of SARS-CoV-2 M-specific memory T cells. In contrast, pre-existing T
348 cells likely recognize various M peptides, possibly including M₁₄₅₋₁₆₀, rather than
349 focusing on this single M peptide, as we observed in epitope mapping analysis.

350 What induces pre-existing M-specific T cells? Common cold coronaviruses may
351 induce pre-existing SARS-CoV-2-specific T cell (22, 23). Amino acid sequence
352 homology between SARS-CoV-2 and other common cold coronaviruses is relatively high
353 for M (NL63: 25.2% , OC43: 36.9%, 229E: 26.7%, HKU1: 32.4%), S1 (NL63: 11.0% ,
354 OC43: 15.4%, 229E: 12.8%, HKU1: 15.2%), S2 (NL63: 27.3% , OC43: 36.9%, 229E:
355 28.0%, HKU1: 35.3%), and N (NL63: 22.3% , OC43: 26.5%, 229E: 16.2%, HKU1:
356 26.5%). These coronaviruses may induce polyclonal M-specific T cells. Age-related loss
357 of memory T cells specific to common cold coronavirus S protein (19) supports the
358 hypothesis that pre-existing M-focused T cell responses are induced by common cold
359 coronavirus infection in elderly people. Our data showing higher frequency of pre-
360 existing T cells specific to S-2 than S-1 are also consistent with the fact that S-2 shows
361 higher homology between SARS-CoV-2 and other coronaviruses. However, some young

362 donors, as well as elderly donors, had abundant pre-existing T cells specific to M, but not
363 to S and N, suggesting that focused T cell responses to M are not necessarily due to age-
364 related loss of pre-existing T cells specific for S and N antigens. Interestingly, a recent
365 study reported that T cells specific to commensal bacteria can cross-react with SARS-
366 CoV-2 S antigen (X. Lu et al., manuscript posted on medRxiv DOI:
367 10.1101/2021.03.23.436573). Similarly, there may be specific microbes that induce pre-
368 existing M-specific T cells.

369 It is worth considering the potential of novel COVID-19 vaccines to induce M-
370 specific immunity. Current vaccine strategies are to induce S-specific antibody and T cell
371 responses (24, 25). Recent studies reported a correlation between the frequency of pre-
372 existing S-specific T cells and vaccine-induced S-specific T cell responses (L. Loyal et
373 al., manuscript posted on medRxiv DOI: 10.1101/2021.04.01.21252379), which suggests
374 a role of pre-existing S-specific T cells in cognate T cell help. However, elderly
375 individuals likely would not benefit fully from pre-existing S-specific T cells. To enhance
376 vaccine efficacy among the elderly, it might be reasonable to consider a strategy to induce
377 not only S-specific, but also M-specific immunity, using vaccines based on inactivated
378 viruses or M-fused S antigens. Linked recognition of M-specific T helper cells by S-
379 specific B cells can promote S-specific antibody production by overcoming the defect of

380 cognate T cell help in elderly individuals. Further characterization of M-specific T cells
381 in young and elderly may provide new insights into vaccine-induced immunity that is less
382 affected by age.

383

384 **Acknowledgements**

385 We thank physicians and nurses at KIN oncology Clinic for excellent support to collect
386 blood samples from donors. We also thank Steven Aird for editing manuscript. We are
387 also grateful to OIST Graduate University for its generous funding of the Immune Signal
388 Unit.

389 **References**

- 390 1. Merad, M., and J. C. Martin. 2020. Pathological inflammation in patients
391 with COVID-19: a key role for monocytes and macrophages. *Nature*
392 *Reviews Immunology* 20: 355-362.
- 393 2. O’Driscoll, M., G. Ribeiro Dos Santos, L. Wang, D. A. T. Cummings, A. S.
394 Azman, J. Paireau, A. Fontanet, S. Cauchemez, and H. Salje. 2021. Age-
395 specific mortality and immunity patterns of SARS-CoV-2. *Nature* 590:
396 140-145.
- 397 3. Takahashi, T., M. K. Ellingson, P. Wong, B. Israelow, C. Lucas, J. Klein, J.
398 Silva, T. Mao, J. E. Oh, M. Tokuyama, P. Lu, A. Venkataraman, A. Park, F.
399 Liu, A. Meir, J. Sun, E. Y. Wang, A. Casanovas-Massana, A. L. Wyllie, C.
400 B. F. Vogels, R. Earnest, S. Lapidus, I. M. Ott, A. J. Moore, A. Shaw, J. B.
401 Fournier, C. D. Odio, S. Farhadian, C. Dela Cruz, N. D. Grubaugh, W. L.
402 Schulz, A. M. Ring, A. I. Ko, S. B. Omer, and A. Iwasaki. 2020. Sex
403 differences in immune responses that underlie COVID-19 disease
404 outcomes. *Nature* 588: 315-320.
- 405 4. Stefan, N., A. L. Birkenfeld, and M. B. Schulze. 2021. Global pandemics
406 interconnected — obesity, impaired metabolic health and COVID-19.

- 407 *Nature Reviews Endocrinology* 17: 135-149.
- 408 5. Krammer, F. 2020. SARS-CoV-2 vaccines in development. *Nature* 586:
409 516-527.
- 410 6. Fajgenbaum, D. C., and C. H. June. 2020. Cytokine Storm. *New England*
411 *Journal of Medicine* 383: 2255-2273.
- 412 7. De Candia, P., F. Prattichizzo, S. Garavelli, and G. Matarese. 2021. T Cells:
413 Warriors of SARS-CoV-2 Infection. *Trends in Immunology* 42: 18-30.
- 414 8. Sattler, A., S. Angermair, H. Stockmann, K. M. Heim, D. Khadzhynov, S.
415 Treskatsch, F. Halleck, M. E. Kreis, and K. Kotsch. 2020. SARS-CoV-2-
416 specific T cell responses and correlations with COVID-19 patient
417 predisposition. *Journal of Clinical Investigation* 130: 6477-6489.
- 418 9. Rydyznski Moderbacher, C., S. I. Ramirez, J. M. Dan, A. Grifoni, K. M.
419 Hastie, D. Weiskopf, S. Belanger, R. K. Abbott, C. Kim, J. Choi, Y. Kato, E.
420 G. Crotty, C. Kim, S. A. Rawlings, J. Mateus, L. P. V. Tse, A. Frazier, R.
421 Baric, B. Peters, J. Greenbaum, E. Ollmann Saphire, D. M. Smith, A. Sette,
422 and S. Crotty. 2020. Antigen-Specific Adaptive Immunity to SARS-CoV-2
423 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*
424 183: 996-1012.e1019.

- 425 10. Chen, G., D. Wu, W. Guo, Y. Cao, D. Huang, H. Wang, T. Wang, X. Zhang,
426 H. Chen, H. Yu, X. Zhang, M. Zhang, S. Wu, J. Song, T. Chen, M. Han, S.
427 Li, X. Luo, J. Zhao, and Q. Ning. 2020. Clinical and immunological features
428 of severe and moderate coronavirus disease 2019. *Journal of Clinical*
429 *Investigation* 130: 2620-2629.
- 430 11. Le Bert, N., H. E. Clapham, A. T. Tan, W. N. Chia, C. Y. L. Tham, J. M.
431 Lim, K. Kunasegaran, L. W. L. Tan, C.-A. Dutertre, N. Shankar, J. M. E.
432 Lim, L. J. Sun, M. Zahari, Z. M. Tun, V. Kumar, B. L. Lim, S. H. Lim, A.
433 Chia, Y.-J. Tan, P. A. Tambyah, S. Kalimuddin, D. Lye, J. G. H. Low, L.-F.
434 Wang, W. Y. Wan, L. Y. Hsu, A. Bertoletti, and C. C. Tam. 2021. Highly
435 functional virus-specific cellular immune response in asymptomatic SARS-
436 CoV-2 infection. *Journal of Experimental Medicine* 218.
- 437 12. Braun, J., L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, S.
438 Hippenstiel, M. Dingeldey, B. Kruse, F. Fauchere, E. Baysal, M. Mangold,
439 L. Henze, R. Lauster, M. A. Mall, K. Beyer, J. Rohmel, S. Voigt, J. Schmitz,
440 S. Miltenyi, I. Demuth, M. A. Muller, A. Hocke, M. Witzernath, N. Suttorp,
441 F. Kern, U. Reimer, H. Wenschuh, C. Drosten, V. M. Corman, C.
442 Giesecke-Thiel, L. E. Sander, and A. Thiel. 2020. SARS-CoV-2-reactive T

443 cells in healthy donors and patients with COVID-19. *Nature* 587: 270-274.

444 13. Le Bert, N., A. T. Tan, K. Kunasegaran, C. Y. L. Tham, M. Hafezi, A. Chia,
445 M. H. Y. Chng, M. Lin, N. Tan, M. Linster, W. N. Chia, M. I. C. Chen, L.-
446 F. Wang, E. E. Ooi, S. Kalimuddin, P. A. Tambyah, J. G.-H. Low, Y.-J. Tan,
447 and A. Bertoletti. 2020. SARS-CoV-2-specific T cell immunity in cases of
448 COVID-19 and SARS, and uninfected controls. *Nature* 584: 457-462.

449 14. Woldemeskel, B. A., A. K. Kwaa, C. C. Garliss, O. Laeyendecker, S. C. Ray,
450 and J. N. Blankson. 2020. Healthy donor T cell responses to common cold
451 coronaviruses and SARS-CoV-2. *Journal of Clinical Investigation* 130:
452 6631-6638.

453 15. Bacher, P., E. Rosati, D. Esser, G. R. Martini, C. Saggau, E. Schiminsky, J.
454 Dargvainiene, I. Schroder, I. Wieters, Y. Khodamoradi, F. Eberhardt, M.
455 Vehreschild, H. Neb, M. Sonntagbauer, C. Conrad, F. Tran, P. Rosenstiel,
456 R. Markewitz, K. P. Wandinger, M. Augustin, J. Rybniker, M. Kochanek, F.
457 Leypoldt, O. A. Cornely, P. Koehler, A. Franke, and A. Scheffold. 2020.
458 Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed
459 Individuals and Humans with Severe COVID-19. *Immunity* 53: 1258-1271
460 e1255.

- 461 16. Chen, Z., and E. John Wherry. 2020. T cell responses in patients with
462 COVID-19. *Nature Reviews Immunology* 20: 529-536.
- 463 17. Sahin, U., A. Muik, E. Derhovanessian, I. Vogler, L. M. Kranz, M. Vormehr,
464 A. Baum, K. Pascal, J. Quandt, D. Maurus, S. Brachtendorf, V. Lörks, J.
465 Sikorski, R. Hilker, D. Becker, A.-K. Eller, J. Grützner, C. Boesler, C.
466 Rosenbaum, M.-C. Kühnle, U. Luxemburger, A. Kemmer-Brück, D.
467 Langer, M. Bexon, S. Bolte, K. Karikó, T. Palanche, B. Fischer, A. Schultz,
468 P.-Y. Shi, C. Fontes-Garfias, J. L. Perez, K. A. Swanson, J. Loschko, I. L.
469 Scully, M. Cutler, W. Kalina, C. A. Kyratsous, D. Cooper, P. R. Dormitzer,
470 K. U. Jansen, and Ö. Türeci. 2020. COVID-19 vaccine BNT162b1 elicits
471 human antibody and TH1 T cell responses. *Nature* 586: 594-599.
- 472 18. Keller, M. D., K. M. Harris, M. A. Jensen-Wachspress, V. V. Kankate, H.
473 Lang, C. A. Lazarski, J. Durkee-Shock, P.-H. Lee, K. Chaudhry, K. Webber,
474 A. Datar, M. Terpilowski, E. K. Reynolds, E. M. Stevenson, S. Val, Z.
475 Shancer, N. Zhang, R. Ulrey, U. Ekanem, M. Stanojevic, A. Geiger, H.
476 Liang, F. Hoq, A. A. Abraham, P. J. Hanley, C. R. Cruz, K. Ferrer, L.
477 Dropulic, K. Gangler, P. D. Burbelo, R. B. Jones, J. I. Cohen, and C. M.
478 Bollard. 2020. SARS-CoV-2-specific T cells are rapidly expanded for

479 therapeutic use and target conserved regions of the membrane protein.
480 *Blood* 136: 2905-2917.

481 19. Saletti, G., T. Gerlach, J. M. Jansen, A. Molle, H. Elbahesh, M. Ludlow, W.
482 Li, B.-J. Bosch, A. D. M. E. Osterhaus, and G. F. Rimmelzwaan. 2020.
483 Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to
484 human coronaviruses OC43 and NL63. *Scientific Reports* 10.

485 20. Jiang, X.-L., G.-L. Wang, X.-N. Zhao, F.-H. Yan, L. Yao, Z.-Q. Kou, S.-X.
486 Ji, X.-L. Zhang, C.-B. Li, L.-J. Duan, Y. Li, Y.-W. Zhang, Q. Duan, T.-C.
487 Wang, E.-T. Li, X. Wei, Q.-Y. Wang, X.-F. Wang, W.-Y. Sun, Y.-W. Gao,
488 D.-M. Kang, J.-Y. Zhang, and M.-J. Ma. 2021. Lasting antibody and T cell
489 responses to SARS-CoV-2 in COVID-19 patients three months after
490 infection. *Nature Communications* 12.

491 21. Ng, O.-W., A. Chia, A. T. Tan, R. S. Jadi, H. N. Leong, A. Bertoletti, and
492 Y.-J. Tan. 2016. Memory T cell responses targeting the SARS coronavirus
493 persist up to 11 years post-infection. *Vaccine* 34: 2008-2014.

494 22. Sagar, M., K. Reifler, M. Rossi, N. S. Miller, P. Sinha, L. F. White, and J. P.
495 Mizgerd. 2021. Recent endemic coronavirus infection is associated with
496 less-severe COVID-19. *Journal of Clinical Investigation* 131.

497 23. Mateus, J., A. Grifoni, A. Tarke, J. Sidney, S. I. Ramirez, J. M. Dan, Z. C.
498 Burger, S. A. Rawlings, D. M. Smith, E. Phillips, S. Mallal, M. Lammers, P.
499 Rubiro, L. Quiambao, A. Sutherland, E. D. Yu, R. Da Silva Antunes, J.
500 Greenbaum, A. Frazier, A. J. Markmann, L. Premkumar, A. De Silva, B.
501 Peters, S. Crotty, A. Sette, and D. Weiskopf. 2020. Selective and cross-
502 reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* 370:
503 89-94.

504 24. Corbett, K. S., D. K. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-
505 Barnum, R. A. Gillespie, S. Himansu, A. Schäfer, C. T. Ziwawo, A. T.
506 Dipiazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch,
507 D. R. Martinez, K. W. Bock, M. Minai, B. M. Nagata, G. B. Hutchinson, K.
508 Wu, C. Henry, K. Bahl, D. Garcia-Dominguez, L. Ma, I. Renzi, W.-P. Kong,
509 S. D. Schmidt, L. Wang, Y. Zhang, E. Phung, L. A. Chang, R. J. Loomis, N.
510 E. Altaras, E. Narayanan, M. Metkar, V. Presnyak, C. Liu, M. K. Louder,
511 W. Shi, K. Leung, E. S. Yang, A. West, K. L. Gully, L. J. Stevens, N. Wang,
512 D. Wrapp, N. A. Doria-Rose, G. Stewart-Jones, H. Bennett, G. S. Alvarado,
513 M. C. Nason, T. J. Ruckwardt, J. S. McLellan, M. R. Denison, J. D. Chappell,
514 I. N. Moore, K. M. Morabito, J. R. Mascola, R. S. Baric, A. Carfi, and B. S.

515 Graham. 2020. SARS-CoV-2 mRNA vaccine design enabled by prototype
516 pathogen preparedness. *Nature* 586: 567-571.

517 25. Polack, F. P., S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart,
518 J. L. Perez, G. Pérez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A.
519 Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R.
520 W. Frenck, L. L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D. B.
521 Tresnan, S. Mather, P. R. Dormitzer, U. Şahin, K. U. Jansen, and W. C.
522 Gruber. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19
523 Vaccine. *New England Journal of Medicine* 383: 2603-2615.

524

525 **Figure Legends**

526 **Fig. 1. Altered pre-existing T cell responses to SARS-CoV-2 structural proteins in**
527 **elderly donors.**

528 PBMCs isolated from seronegative (**A**) and seropositive (**B**) young (20-50 years of age)
529 and elderly (>70 years of age) donors were stimulated with peptide pools for SARS-CoV-
530 2 S, N, and M proteins and subjected to IFN- γ ELISpot analysis. Spot-forming units
531 representing the frequency of IFN- γ -secreting cells in seronegative young (n=45),
532 seronegative elderly (n=41), seropositive young (n=19), and seropositive elderly (n=11)
533 are shown. The sum of spots formed by cells stimulated with S, N, and M (SNM) is also
534 shown. Statistical comparisons between age groups utilized the Mann-Whitney test.
535 *P<0.05, ns: not significant.

536

537 **Fig. 2. M-specific pre-existing T cell responses predominate in elderly donors.**

538 Ratios of spots formed by cells stimulated with SARS-CoV-2 S, N, and M peptide pools
539 in ELISpot data (in Fig. 1.) were analyzed in seronegative (**A**) and seropositive (**B**) donors
540 who had >40 spots/ 10^6 PBMCs in the sum of spots formed by cells stimulated with S, N,
541 and M.

542

543 **Fig. 3. Pre-existing and SARS-CoV-2-induced M-specific T cells exhibit similar**
544 **phenotypes.**

545 PBMCs isolated from seronegative (n=5) and seropositive (n=5) M responders were
546 stimulated with an M peptide pool for 7 hours and analyzed by flow cytometry. The flow
547 cytometry gating strategy was shown in Supplemental Figure 1. (A) Dot plots represent
548 IFN- γ expression in CD4 and CD8 T cells of subject #31 (seronegative, >70 years of age).
549 (B) Percentages of IFN- γ -expressing cells among CD4 and CD8 T cells were analyzed.
550 (C) Percentages of naïve (Tn), central memory (Tcm), and effector memory (Tem) among
551 IFN- γ -expressing cells stimulated with M. (D, E) Percentages of TNF- α - and IL-2-
552 expressing cells among total CD4 T cells (D) and IFN- γ -expressing CD4 T cells (E)
553 stimulated with M. (B-E) Data shown as mean \pm SD. Each dot represents an individual
554 donor. Blue and orange dots indicate results of young and elderly donors, respectively.
555 Statistical analysis utilized unpaired two-tailed Student's t tests. *P<0.05, ns: not
556 significant.

557

558 **Fig. 4. SARS-CoV-2 M epitopes recognized by T cells.**

559 PBMCs isolated from M responders in seropositive (A) and seronegative (B) groups were
560 stimulated with SARS-CoV-2 M matrix pools (15 pools) for 16 h and subjected to IFN- γ

561 ELISpot analysis. Spot-forming units representing the frequency of IFN- γ -secreting cells.

562 Blue and orange bars indicate results of young and elderly donors, respectively.

563

Figure 1






Figure 2

A



B




Figure 3





Figure 4

A



B

